Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Detaylı Bibliyografya
Asıl Yazarlar:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Elsevier 2023-12-01
Seri Bilgileri:	Translational Oncology
Konular:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Benzer Materyaller

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
Yazar:: Hana Garaj, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
Yazar:: Senar Ebinç, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
Yazar:: Wu L, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
Yazar:: Katarina Mirjačić Martinović, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
Yazar:: Dugan MM, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
Yazar:: Polsky David, ve diğerleri
Baskı/Yayın Bilgisi: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
Yazar:: Francesca Consoli, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
Yazar:: Jacek Calik, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
Yazar:: Xiang Dan, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
Yazar:: I. V. SAMOILENKO, ve diğerleri
Baskı/Yayın Bilgisi: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
Yazar:: Ernesto Rossi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
Yazar:: Lance Wollenberg, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
Yazar:: Bartoušková Marie, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
Yazar:: Justin C. Moser, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
Yazar:: Yu. S. Shakh-Paronyants, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Yazar:: Dahlia Fedele, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Yazar:: Saba S. Shaikh, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Melanoma: BRAFi Rechallenge
Yazar:: Christoforos S. Kosmidis, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
Yazar:: Milena Cavic, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
Yazar:: Sarkisian S, ve diğerleri
Baskı/Yayın Bilgisi: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
Yazar:: Lazaro Hiram Betancourt, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
Yazar:: Enrica Teresa Tanda, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
Yazar:: Marco Ghezzi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-03-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
Yazar:: Rozala Arko, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
Yazar:: Ahmed Temirak, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
Yazar:: Pinakin Pandya, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
Yazar:: Peter Mohr, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
Yazar:: Karam Khaddour, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
Yazar:: Igor V. Samoylenko, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
Yazar:: Adi Kartolo, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
Yazar:: Simeng Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
Yazar:: Clara So, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
Yazar:: Julia Kuchnicka, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
Yazar:: Taku Fujimura, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
Yazar:: Elodie Long-Mira, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
Yazar:: Walid Shalata, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
Yazar:: Nakul Dar, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
Yazar:: Lena Groennendijk, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
Yazar:: Francesco Serra, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
Yazar:: O. I. Kit, ve diğerleri
Baskı/Yayın Bilgisi: (2016-06-01)